Related Experiment Video
Updated: May 24, 2026
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Clinical development of new formulations of cytotoxics in solid tumors
1Breast Cancer Translational Research Laboratory (BCTL) J.C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Purpose Of Review:
To discuss the clinical development of new formulations of old cytotoxic agents and highlight the value of adopting this strategy.
Recent Findings:
Several drugs are currently in clinical development with high potential in improving clinical outcomes compared with their older counterparts. We emphasize on the results of four of these agents, each belonging to a known group of cytotoxics namely amrubicin, EndoTAG-1, pralatrexate and NKTR-102. Each has shown promising results that have the potential in addressing some limitations that have been observed with the 'earlier generation' agents.
Summary:
Improvement in drug development strategies and the appreciation of the mechanisms of action and resistance of the cytotoxic agents currently available in the clinic open the door for developing agents that have the potential of improving clinical outcomes with better safety profiles. It is important to adopt innovative clinical trials designs integrating molecular markers in early clinical development in order to identify the subgroups of patients who would derive the maximal benefit of these novel agents.
Insights
New formulations of cytotoxic chemotherapy drugs are in development, showing promise for improved outcomes and safety. This strategy leverages existing drug classes to overcome limitations of older agents.
Area of Science:
- Oncology
- Pharmacology
- Drug Development
Background:
- Cytotoxic chemotherapy agents are mainstays in cancer treatment.
- Older cytotoxic drugs often have limitations including toxicity and resistance.
- Developing new formulations can potentially overcome these limitations.
Purpose of the Study:
- To review the clinical development of novel formulations of established cytotoxic agents.
- To highlight the strategic value of reformulating existing cytotoxic drugs.
- To discuss the potential of these new agents in improving cancer treatment outcomes.
Main Methods:
- Review of clinical development data for new cytotoxic formulations.
- Emphasis on four specific agents: amrubicin, EndoTAG-1, pralatrexate, and NKTR-102.
- Analysis of their potential to address limitations of earlier generation agents.
Main Results:
- Several new cytotoxic formulations demonstrate significant clinical potential.
- Amrubicin, EndoTAG-1, pralatrexate, and NKTR-102 show promising results in early development.
- These agents offer potential improvements over their predecessors in efficacy and/or safety.
Conclusions:
- Advancements in drug development and understanding of resistance mechanisms enable improved cytotoxic agents.
- Novel cytotoxic agents offer potential for better clinical outcomes and safety profiles.
- Innovative clinical trial designs incorporating molecular markers are crucial for identifying patient subgroups benefiting from these new agents.
Related Concept Videos
01:28Preclinical Development: Overview
01:11Clinical Trials: Overview